Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Takeda Pharmaceutical Co., Ltd. (OTC: TKPYY).

Full DD Report for TKPYY

You must become a subscriber to view this report.


Recent News from (OTC: TKPYY)

Takeda Pharmaceutical Co., Ltd. 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Takeda Pharmaceutical Co., Ltd. in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: May, 15 2018 13:31
Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea...
Source: SeekingAlpha
Date: May, 09 2018 01:40
Takeda Pharmaceutical (TKPYY) to Acquire Shire (SHPG) - Slideshow
The following slide deck was published by Takeda Pharmaceutical Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 08 2018 14:02
Novo Nordisk: An Objective Analysis
In January 2017 I analyzed the major pharmaceuticals sector which resulted in a buy recommendation for Novo Nordisk. The analysis included a target price, which was hit in September. I looked at the company again in October and new financials led to a new valuation, and as it turned out, a n...
Source: SeekingAlpha
Date: May, 08 2018 10:48
News On Iran And Venezuela, And Takeda Closes The Deal (Wall Street Breakfast Podcast)
Get today's Wall Street Breakfast in podcast form to listen on the go. Today’s top stories: Investors await President Trump’s Iran nuclear deal decision; the US has issued Venezuelan sanctions to those with ties to President Maduro; and Takeda is set to acquire Shire. ...
Source: SeekingAlpha
Date: May, 08 2018 08:07
Wall Street Breakfast: Fate Of The Iran Nuclear Deal?
Investors are getting ready for President Trump's big decision today on the Iran nuclear accord, which will affect everything from U.S. alliances to trade partnerships and the oil market. Expectations are high that he will exit the deal, but questions remain on how quickly the admi...
Source: SeekingAlpha
Date: May, 08 2018 07:00
Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update
Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu...
Source: SeekingAlpha
Date: May, 08 2018 03:34
Takeda Activities at American Psychiatric Association (APA) Annual Meeting Innovation Zone Highlight Advancements in Mental Health
DEERFIELD, Ill. , May 5, 2018 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A. , Inc. ("Takeda") will lead two panel discussions at the American Psychiatric Association (APA) 2018 Annual Meeting Mental Health Innovation Zone to explore how innovations in neuroscience and digital technology ...
Source: PR Newswire
Date: May, 05 2018 15:00
FDA Finds Mallinckrodt's Supplemental NDA For Amitiza Lacking
April was supposed to be a big month for Mallinckrodt ( MNK ) and newly acquired Sucampo Pharmaceuticals. Sucampo's main drug, Amitiza (lubiprostone), treats chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced co...
Source: SeekingAlpha
Date: May, 04 2018 02:18
TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
OSAKA, Japan and DEERFIELD, Ill. , May 2, 2018 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRI...
Source: PR Newswire
Date: May, 02 2018 17:36

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1420.6320.61520.6520.53343,415
2018-08-1321.18320.87521.1920.85297,479
2018-08-1021.0520.9021.1420.85282,549
2018-08-0921.33521.4321.48521.27212,467
2018-08-0821.4221.3521.4221.29273,420

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1423,252343,2156.7748Cover
2018-08-1379,744297,47926.8066Cover
2018-08-10142,282282,54950.3566Short
2018-08-0954,004212,46725.4176Cover
2018-08-08164,702273,42060.2377Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TKPYY.


About Takeda Pharmaceutical Co., Ltd. (OTC: TKPYY)

Logo for Takeda Pharmaceutical Co., Ltd. (OTC: TKPYY)

Research amp Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.

 

Contact Information

 

 

Current Management

  • Yasuchika Hasegawa / President

Current Share Structure

  • Market Cap: $41,994,442,932 - 03/09/2018
  • Issue and Outstanding: 789,666,095 - 06/30/2013

 



Daily Technical Chart for (OTC: TKPYY)

Daily Technical Chart for (OTC: TKPYY)


Stay tuned for daily updates and more on (OTC: TKPYY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TKPYY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TKPYY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of TKPYY and does not buy, sell, or trade any shares of TKPYY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/